Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01112306 · ClinicalTrials.gov registry record · Phase 3
ACT-293987 in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 709
- Enrollment target
NCT01112306 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 709 participants.
The verdict
NCT01112306, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 709 participants
- Enrollment target
Study Summary
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
Interventions
- DRUG ACT-293987
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2010-07-07 |
| Est. Completion | 2021-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01112306
The ClinicalTrials.gov registry entry for NCT01112306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 709 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACT-293987 is the first listed.
NCT01112306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01112306 about?
NCT01112306 is a clinical study titled "ACT-293987 in Pulmonary Arterial Hypertension". Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
What is the current status of trial NCT01112306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 709 participants. The study started on 2010-07-07. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT01112306?
The interventions under investigation include: ACT-293987 (DRUG).
Who is sponsoring clinical trial NCT01112306?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.